Pulmonary hypertension
Also known as: Pulmonary vascular hypertension, Elevated pulmonary arterial pressure, Pulmonary arterial hypertension (Group 1 subtype), Chronic thromboembolic pulmonary hypertension (Group 4 subtype)
Pulmonary hypertension is characterised by pathologically elevated mean pulmonary arterial pressure. Etiology involves diverse clinical groups that may culminate in right-sided heart failure. This condition is distinct from systemic arterial hypertension and necessitates specialist classification and management. TCM assessment provides a framework for supportive care in medically stable patients; it is not a primary intervention for reducing pulmonary pressure or modifying disease progression. Cited herbal evidence is largely restricted to experimental models and mechanisms rather than established clinical efficacy for the listed formulas. Furthermore, acupuncture evidence pertains to systemic rather than pulmonary hypertension; direct clinical evidence for acupuncture in this condition is currently absent. Safety guidance serves as a clinical safeguard rather than a finding derived from these abstracts.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to the exercise regimen prescribed by the pulmonary hypertension team, ceasing activity and seeking clinical advice if dizziness, chest pain, or disproportionate breathlessness occurs.
- •Maintain sodium and fluid intake within the parameters specified by the medical team; monitor body weight and peripheral oedema as directed.
- •Cease tobacco and nicotine inhalation; consult a specialist prior to air travel or high-altitude exposure.
- •Ensure strict compliance with all medications, supplemental oxygen, vaccinations, and specialist reviews; initiate early consultation regarding pregnancy planning due to significant maternal and foetal risks.
Cautions & Contraindications
- •Do not initiate acupuncture or herbs during suspected decompensation or unexplained worsening symptoms, and never delay emergency or specialist treatment. Citation [1] supports the seriousness of PH; it does not validate this precaution as a trial finding.[]
- •Do not select acupuncture to lower pulmonary artery pressure on the basis of systemic-hypertension results. The supplied systemic-hypertension review does not establish PH efficacy or safety in unstable PH.[]
- •Do not start a formula without medication reconciliation and specialist approval, particularly with anticoagulants, prostacyclin therapies, diuretics or digoxin. The experimental herbal review does not establish these combinations as safe; interaction cautions here are clinical safeguards.[]
- •Avoid deep thoracic needling because of pneumothorax risk and avoid infected skin, vascular-access sites and markedly oedematous tissue. An absence of confirmed serious events in the systemic-hypertension review does not establish safety for PH or these sites.[]
When to reassess or seek care again
For medically stable patients, review any adjunctive trial within 1–2 weeks and formally at 4 weeks. Record fatigue and breathlessness on consistent 0–10 scales, appetite, sleep, adverse effects and ability to complete a familiar activity without provoking symptoms. Track weight, blood pressure and oxygen saturation only within the specialist's monitoring plan. Stop and refer for worsening symptoms, new oedema, bleeding or symptomatic hypotension; cease an ineffective trial after 4 weeks. PH haemodynamics and formal exercise testing remain specialist responsibilities.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Journal of ethnopharmacology · 2026
- Drug design, development and therapy · 2026
- Frontiers in medicine · 2026
- Molecular biology reports · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
